drugset / Trial / NCT05508009

Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor

NCT05508009

Non-randomizedSequentialOpen-labelTreatment

Summary

This is a single center, non-randomized, non-controlled open-label phase 1b/2a trial of performing sequential αβdepleted-HSCT and KT in patients requiring KT to prevent kidney rejection post-KT, in the absence of any post-KT immunosuppression, to abrogate the need for lifelong immunosuppression, the risk of chronic rejection and, ultimately, the need for repeated transplantation.

Timeline

Start
2023-01-10
Primary completion
2032-10
Completion
2034-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 100 mg/kg
Subject Cyclophosphamide Other / unclassified 1200 mg/kg
Subject Fludarabine Small molecule 0.5 mg/kg
Subject Melphalan Small molecule 100 mg/m2
Background Rituximab Monoclonal antibody 200 mg/m2